<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04089150</url>
  </required_header>
  <id_info>
    <org_study_id>CTC 0245/AGITG AG0118PS</org_study_id>
    <nct_id>NCT04089150</nct_id>
  </id_info>
  <brief_title>MFOLFIRINOX And Stereotactic Radiotherapy (SBRT) for Pancreatic Cancer With High Risk and Locally Advanced Disease</brief_title>
  <acronym>MASTERPLAN</acronym>
  <official_title>MASTERPLAN: A Randomised Phase II Study of MFOLFIRINOX And Stereotactic Radiotherapy (SBRT) for Pancreatic Cancer With High Risk and Locally Advanced Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Australasian Gastro-Intestinal Trials Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Trans-Tasman Radiation Oncology Group (TROG)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Australian Government Department of Health and Ageing</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Australasian Gastro-Intestinal Trials Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multicentre randomised, phase II clinical trial, with randomisation
      2:1 by minimisation and stratification by tumour stage, planned chemotherapy and institution.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multicentre randomised, phase II clinical trial to evaluate safety and
      activity of stereotactic body radiotherapy (SBRT) in addition to chemotherapy in patients
      with high-risk and borderline resectable pancreatic cancer (BRPC) and locally advanced
      pancreatic cancer (LAPC). High risk defined as any patient with tumour &gt;4cm, extrapancreatic
      extension or node positive disease.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2019</start_date>
  <completion_date type="Anticipated">August 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Locoregional control (Locoregional Response Rate LRR)</measure>
    <time_frame>Within 12 months of randomisation;</time_frame>
    <description>To determine if the addition of SBRT to chemotherapy improves locoregional control;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety (NCI CTCAE v5.0)</measure>
    <time_frame>Safety Assessment before each cycle of chemotherapy, post chemotherapy treatment, following SBRT and surgery (if applicable) then at 3, 6, 9 and 12 months post-randomisation and 6 monthly during year 2, 3 and 4</time_frame>
    <description>Compare acute and late side effects from chemotherapy +/- SBRT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical morbidity/mortality (Clavien grading system)</measure>
    <time_frame>At discharge post-surgery, 30 days and 90 days post surgery, up to 4 years</time_frame>
    <description>Length of stay, death within 30 days, frequency and severity of adverse events. Hospital admission during surgery will be calculated from day of surgery to date of discharge from acute care hospitalisation. The length of stay in acute hospital care will include intensive care admissions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiological response rates (RECIST v1.1)</measure>
    <time_frame>at baseline. In SBRT arm, post-initial chemotherapy (prior to SBRT). In both arms, 4-6 weeks post completion of initial treatment (prior to surgery), 3 ,6, 9 and 12 monthly during year 2, 3 and 4.</time_frame>
    <description>Compare radiologic response rates for chemotherapy +/- SBRT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS) (RECIST v1.1)</measure>
    <time_frame>From randomisation to the time of first documented clinical or imaging relapse or date of death from any cause, whichever occurs first; up to 4 years</time_frame>
    <description>Compare 12-month progression free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathological response rates (College of American Pathology Tumour Regression Grade TRG)</measure>
    <time_frame>At SRBT/surgery compared to baseline;</time_frame>
    <description>Compare pathologic response rates of chemotherapy +/- SBRT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical resection rates (Guidelines for the Evaluation of Resectability and Histology)</measure>
    <time_frame>At surgery</time_frame>
    <description>Compare rates of surgical resection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>R0 resection rates (&gt;1mm) (Synoptic PC histology reporting as outlined in Royal College of Pathologists of Australasia (RCPA)</measure>
    <time_frame>At surgery</time_frame>
    <description>Compare R0 resection rates (&gt;1 mm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (EORTC QLQ C30 and PAN26 QOL)</measure>
    <time_frame>Baseline, Day 1 of each cycle of chemotherapy, prior to SBRT, post initial chemotherapy +/- SBRT, prior to surgery, 30 days post end of treatment, at months 3, 6,9 and 12 post randomisation 6 monthly in years 2, 3 and 4.</time_frame>
    <description>To assess the impact of the regimens on quality of life of patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Deterioration-Free Survival (DFS) (EORTC QLQ C30)</measure>
    <time_frame>The time until the first of the following events: a 10-point deterioration in health status from baseline, disease progression, death, or treatment discontinuation;up to 4 years</time_frame>
    <description>To assess overall net clinical benefit of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>From the date of randomisation to date of death from any cause, or the date of last known alive; up to 4 years</time_frame>
    <description>OS is defined as the interval from the date of randomisation to date of death from any cause, or the date of last known alive. Participants will be censored at the date of commencement of the subsequent anti-cancer therapy.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Exploratory biomarker analysis of blood</measure>
    <time_frame>baseline, prior to SBRT (Arm B only), insertion of fiducial markers (Arm B, optional), post initial treatment, at surgery (optional, at selected sites), 6 and12 months post randomisation and at progression, up to 5 years</time_frame>
    <description>The list of blood biomarkers and their measurement will be updated when confirmed.</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory biomarker analysis of tissue</measure>
    <time_frame>Diagnosis (archival tissue), at time of fiducial insertion (Arm B, optional), surgical resection (for resectable patients) and at time of progression (optional), up to 5 years.</time_frame>
    <description>The list of tissue biomarkers and their measurement will be updated when confirmed.</description>
  </other_outcome>
  <other_outcome>
    <measure>ePRO Acceptability</measure>
    <time_frame>Baseline, Day 1 of each cycle of chemotherapy, 2 weeks post initial chemotherapy(SBRT arm), 4-6 weeks post initial chemotherapy +/- SBRT, 30 days post end of treatment, at months 3, 6,9 and 12 post randomisation 6 monthly in years 2, 3 and 4.</time_frame>
    <description>Proportion of patients who are willing to use electronic device vs. paper format, Analysis of demographic data and assessing data quality between the group</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Option 1: fluorouracil(5-FU)/leucovorin/irinotecan/oxaliplatin (mFOLFIRINOX) (6 cycles)
Option 2: gemcitabine + nab-paclitaxel (3 cycles)
Resectable patients receive surgery 6 weeks post completion of initial chemotherapy
Unresectable patients continue with ongoing chemotherapy (option 1 or option 2)
Unresectable patients with locoregional progression or metastatic disease, chemotherapy treatment at the discretion of treating medical oncologist
Adjuvant chemotherapy for resectable patients to begin within 8 weeks after surgery
For patients who received option 1 chemotherapy: 12 weeks of mFOLFIRINOX
For patients who received option 2 chemotherapy: 12 weeks of mFOLFIRINOX or 12 additional weeks of gemcitabine/capecitabine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Option 1: fluorouracil(5-FU)/leucovorin/irinotecan/oxaliplatin (mFOLFIRINOX) (6 cycles)
Option 2: gemcitabine + nab-paclitaxel (3 cycles)
Stereotactic Radiotherapy (SBRT) to commence within 3 weeks of completing initial chemotherapy: 40 Gray (Gy) in 5 fractions over 2 weeks
Resectable patients receive surgery 6 weeks post completion of initial chemotherapy
Unresectable patients continue with ongoing chemotherapy (option 1 or option 2)
Unresectable patients with locoregional progression or metastatic disease, chemotherapy treatment at the discretion of treating medical oncologist
Adjuvant chemotherapy for resectable patients to begin within 8 weeks after surgery
For patients who received option 1 chemotherapy: 12 weeks of mFOLFIRINOX
For patients who received option 2 chemotherapy: 12 weeks of mFOLFIRINOX or 12 additional weeks of gemcitabine/capecitabine</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic Radiotherapy (SBRT)</intervention_name>
    <description>40 Gray (Gy) in 5 fractions, 2-3 fractions per week over two weeks, 8 Gy per fraction</description>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>SBRT</other_name>
    <other_name>Stereotactic Body Radiotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mFOLFIRINOX</intervention_name>
    <description>Day 1: oxaliplatin 85mg/m2 + irinotecan 150mg/m2 + leucovorin 50mg
5-FU 2400mg/m2 continuous IV infusion, 46 hour continuous infusion
14-day cycle, 6 cycles</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>modified regimen of oxaliplatin, leucovorin, irinotecan, and fluorouracil (5-FU)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine + Nab-paclitaxel</intervention_name>
    <description>Day 1, Day 8 and Day 15 gemcitabine 1000mg/m2 + nab-paclitaxel 125mg/m2
28-day cycle, 3 cycles</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Gemcitabine + Abraxane</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine + Capecitabine</intervention_name>
    <description>Week 1, 2 and 3, qw: 1000 mg/m2 gemcitabine
21 days continuous: 830 mg/m2 oral capecitabine + 7 days rest
28-day cycle, 3 cycles</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>GemCap</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pancreatoduodenectomy (Whipple procedure)</intervention_name>
    <description>R0 resection. When the tumour is within the head of the pancreas, a standard Whipple's procedure and level 2/3 dissection with modification to obtain margin clearance will be offered. For lesions in the tail, a standard modular resection will be offered.</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Whipple</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults, aged between 18-75 years, with histological confirmation of pancreatic
             adenocarcinoma

          -  Any of the following

               1. T3 (tumour &gt;4 cm)

               2. Extrapancreatic extension

               3. Node positive (stage IIB)

               4. Borderline resectable pancreatic cancer, locally advanced pancreatic cancer

          -  Measurable disease according to RECIST v1.1

          -  ECOG performance status 0-1

          -  Adequate renal and haematological function

          -  Adequate hepatic function. Defined as bilirubin &lt;1.5 X ULN (Upper Limit of Normal),
             AST + ALT &lt;3.0 X ULN. In patients who have had a recent biliary drainage and whose
             bilirubin is descending, a value of â‰¤ 3 X N is acceptable

          -  Study treatment planned to start within 14 days of registration

          -  Willing and able to comply with all study requirements, including treatment, timing
             and/or nature of required assessments

          -  Signed, written informed consent

        Exclusion Criteria:

          -  Tumour size greater than 70mm

          -  Prior abdominal radiotherapy

          -  Evidence of metastatic disease on baseline radiologic investigations

          -  History of another malignancy within 2 years prior to randomisation, except adequately
             treated carcinoma-in-situ, basal cell carcinoma of the skin, squamous cell carcinoma
             of the skin, superficial transitional cell carcinoma of the bladder, or any Stage 1
             endometrial carcinoma. Patients with a history of other malignancies are eligible if
             they have been continuously disease free for at least 2 years after definitive primary
             treatment

          -  Concurrent illness, including severe infection that may jeopardise the ability of the
             patient to undergo the procedures outlined in this protocol with reasonable safety

          -  Neuroendocrine pancreatic carcinoma

          -  Life expectancy of less than 3 months

          -  Pregnancy, lactation, or inadequate contraception. Women must be post-menopausal,
             infertile, or use a reliable means of contraception. Women of childbearing potential
             must have a negative pregnancy test done within 7 days prior to registration. Men must
             use a reliable means of contraception

          -  Serious medical or psychiatric conditions that might limit the ability of the patient
             to comply with the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Oar</last_name>
    <role>Study Chair</role>
    <affiliation>ICON Gold Coast University Hospital, Southport, Queensland, AUS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>NHMRC CTC</last_name>
    <phone>+61 (0) 2 9562 5000</phone>
    <email>masterplan@ctc.usyd.edu.au</email>
  </overall_contact>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>February 4, 2019</study_first_submitted>
  <study_first_submitted_qc>September 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2019</study_first_posted>
  <last_update_submitted>September 11, 2019</last_update_submitted>
  <last_update_submitted_qc>September 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stereotactic body radiotherapy</keyword>
  <keyword>SBRT</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>radiotherapy</keyword>
  <keyword>surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The study will be conducted in accordance with applicable Privacy Acts and Regulations. All data generated in this study will remain confidential. All information will be stored securely at the NHMRC CTC, University of Sydney and will only be available to people directly involved with the study.
Personal data identifying trial participants will be held securely at the NHMRC CTC for the purpose of follow up if the patient is unable to/wishes to discontinue clinic based follow-up.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

